文献速递冠心病外科

慢性肾病患者冠脉搭桥术后替格瑞洛与阿司匹林比较

Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease.
PubMed 文献 · Ann Thorac Surg · 2021-04-02

该研究为TiCAB试验的事后分析,比较替格瑞洛与阿司匹林在合并与不合并慢性肾病(CKD)的冠脉搭桥患者中的疗效与安全性。CKD患者1年MACCE和大出血发生率均高于非CKD患者;在CKD患者中,替格瑞洛组MACCE发生率高于阿司匹林组,大出血无差异。

要点

  • CKD患者冠脉搭桥术后1年MACCE和大出血风险均高于非CKD患者。
  • CKD患者使用替格瑞洛较阿司匹林1年MACCE发生率更高。
  • CKD患者中替格瑞洛与阿司匹林的大出血发生率无显著差异。

核心结论

  • 在合并CKD的冠脉搭桥患者中,替格瑞洛组MACCE发生率高于阿司匹林组,但大出血发生率相似。

研究设计与样本

  • TiCAB试验的事后分析,共纳入1843例随机患者,其中276例(15%)存在CKD。

临床怎么用

  • 对于合并CKD的冠脉搭桥术后患者,选择抗血小板药物时需权衡替格瑞洛增加MACCE的风险。

局限性

  • 该分析为TiCAB试验的事后分析,CKD亚组样本量较小(276例),结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal antiplatelet therapy for patients with chronic kidney disease (CKD) undergoing coronary artery bypass graft surgery remains unknown. METHODS: This post hoc analysis of the Ticagrelor in Coronary Artery Bypass (TiCAB) trial examined the efficacy and safety of ticagrelor vs aspirin in patients with and patients without CKD. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), namely, the composite of cardiovascular death, stroke, myocardial infarction, or revascularization at 1 year after coronary artery bypass graft surgery. Secondary endpoints included individual components of the primary endpoint, all-cause death, and major bleeding. RESULTS: Chronic kidney disease was present in 276 of 1843 randomized patients (15%). Patients with CKD vs patients without CKD had higher 1-year rates of MACCE (13% vs 8.3%, hazard ratio [HR] 1.63; 95% confidence interval [CI], 1.12 to 2.39; P = .01) and major bleeding (5.6% vs 3.1%, HR 1.84; 95% CI, 1.03 to 3.28; P = .04). The 1-year rate of MACCE was increased with ticagrelor vs aspirin in patients with CKD (18.2% vs 8.9%, HR 2.15; 95% CI, 1.08 to 4.30; P = .03), but not in patients without CKD (8.5% vs 8.1%, HR 1.05; 95% CI, 0.74 to 1.49; P = .79; Pinteraction = .067). There was no difference in the 1-year rate of major bleeding with ticagrelor vs aspirin in patients with CKD (6.6% vs 4.7%, HR 1.44; 95% CI, 0.52 to 3.97; P = .48) and patients without CKD (3.3% vs 2.9%, HR 1.14; 95% CI, 0.64 to 2.01; P = .65). CONCLUSIONS: Among patients with CKD and coronary artery bypass graft surgery, those who received ticagrelor had a higher incidence of MACCE but a similar incidence of major bleeding compared with those who received aspirin.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Sandner SE, Schunkert H, Kastrati A, et al. Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease. Ann Thorac Surg. 2021. PMID: 33819474. doi:10.1016/j.athoracsur.2021.03.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。